Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MECP2 | P51608 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13886476 | 1.00 | TEK (0.48) | TEKKDREPHB4TSHRRECQL | |
| SCHEMBL13872400 | 0.87 | HSD17B1 (0.44) | TEKKDRKDM4EBRD4 | |
| SCHEMBL12277854 | 0.81 | TEK (0.53) | TEKKDREPHB4TSHRALDH1A1 | |
| SCHEMBL14987759 | 0.80 | TEK (0.55) | TEKKDREPHB4NPC1RAB9A | |
| SCHEMBL19535125 | 0.79 | KDR (0.48) | TEKKDREPHB4TSHRMEN1 | |
| SCHEMBL2659922 | 0.79 | KEAP1 (0.46) | TSHRALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL13220233 | 0.79 | MECP2 (0.49) | TEKKDREPHB4TSHRRECQL | |
| SCHEMBL2742892 | 0.79 | CHRNB2 (0.49) | KDM4EMEN1MAPTKMT2ACA12 | |
| SCHEMBL16264699 | 0.79 | TEK (0.57) | TEKKDREPHB4TSHRRECQL | |
| SCHEMBL29980249 | 0.79 | TEK (0.45) | TEKKDREPHB4TSHRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115701996-B | Combination of CBP/p300 bromodomain inhibitors and EGFR inhibitors for the treatment of EGFR mutant NSCLC | 托雷莫治疗股份公司 | 2024-12-24 | — | — | CN | disclosed |
| EP-4320109-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | Tolremo Therapeutics AG (CH) | 2024-02-14 | — | — | EP | disclosed |
| CN-117355512-A | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | 托雷莫治疗股份公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-116113417-A | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic diseases | 托雷莫治疗股份公司 | 2023-05-12 | — | — | CN | disclosed |
| EP-4171557-A1 | COMBINATION OF A CBP/P300 BROMODOMAIN INHIBITOR AND A KRAS INHIBITOR FOR THE TREATMENT OF CANCER | Tolremo Therapeutics AG (CH) | 2023-05-03 | — | — | EP | disclosed |
| EP-4171556-A1 | A COMBINATION OF A CBP/P300 BROMODOMAIN INHIBITOR AND AN EGFR INHIBITOR FOR USE IN TREATING EGFR-MUTANT NSCLC | Tolremo Therapeutics AG (CH) | 2023-05-03 | — | — | EP | disclosed |
| EP-4171562-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF FIBROTIC DISEASE | Tolremo Therapeutics AG (CH) | 2023-05-03 | — | — | EP | disclosed |
| CN-115996717-A | Combination of CBP/P300 bromodomain inhibitors and KRAS inhibitors for the treatment of cancer | 托雷莫治疗股份公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-115701996-A | Combination of a CBP/p300 bromodomain inhibitor and an EGFR inhibitor for the treatment of EGFR mutant NSCLC | 托雷莫治疗股份公司 | 2023-02-14 | — | — | CN | disclosed |
| CN-115697974-A | Imidazole 3-oxide derivative based ACSS2 inhibitors and methods of use thereof | 美特波米德有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2022214606-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2022-10-13 | — | — | WO | disclosed |